Filter By:

Completed

CTN 102: Nelfinavir versus Ritonavir (NvR)

A Randomized Trial of the Efficacy and Safety of Nelfinavir vs. Ritonavir added to Background Antiretroviral Nucleoside Therapy in HIV-Infected Individuals with CD4+ Cell Counts < 100 mm3: Trial results

Learn More

Completed

CTN 101: Hydrea in Combination

A randomized study of antiviral activity and safety of combinations of didanosine, stavudine, zidovudine, and/or hydrea in anti-retroviral treatment-naive HIV-infected subjects: Trial results

Learn More

Completed

CTN 094: AZT/3TC/Nelfinavir (AVANTI III)

A Randomized, Double-blind, comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV-1 infection. (AVANTI-Project 113; Protocol 067C): Trial results

Learn More

Completed

CTN 093: Nevirapine/3TC

An International, Double-blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety and Effectiveness of Nevirapine in Preventing Clinical AIDS Progression Events or Death when Used in Combination with 3TC and Stable (4wks) Background Nucleoside Therapy: Trial results

Learn More

Completed

CTN 091: Mixed Carotenoids

A Randomized Clinical Trials of Daily Multivitamin with or without Mixed Carotenoid Supplementation in Advanced HIV Disease: Trial results

Learn More

Completed

CTN 090: AZT/3TC/Indinavir (AVANTI II)

A Randomized, Double-blind, Comparative Trial to Evaluate the Efficacy, Safety and Tolerance of Combination Antiretroviral Regimens for the Treatment of HIV-1 Infection: Trial results

Learn More

Completed

CTN 089: AZT/3TC/Loviride (AVANTI I)

A Randomized, Double-blind, Comparative Trial to Evaluate the Efficacy, Safety and Tolerance of Combination Antiretroviral Regimens for Treatment of HIV-1 Infection: AZT/3TC vs AZT/3TC/Loviride in Antiretroviral Naïve Patients: Trial results

Learn More

Completed

CTN 086: Isoniazid versus Rifabutin

A Phase III Controlled, Double-Blind, Randomized, Multinational Study for the Preventative Therapy of Latent Tuberculosis in HIV-positive Individuals: Isoniazid (300 mg/day x 12 months ) vs. Rifabutin (300 mg/day x 3 months)

Learn More

Completed

CTN 083: LiGLA

A Phase I Open-Label Study of the Safety and Potential Efficacy of LiGLA (EF-13) in Advanced HIV Infection

Learn More
Canadian Association for HIV Research

CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.